Table of contents


On 20 October 2004, orphan designation (EU/3/04/227) was granted by the European Commission to Orphix Consulting GmbH, Germany, for 1, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane for treatment to mobilize progenitor cells prior to stem cell transplantation. The sponsorship was transferred to Genzyme Europe BV, the Netherlands, in June 2007.

l, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane has been authorised in the EU as Mozobil since 31 July 2009.

The sponsor’s address was updated in December 2018.

Key facts

Active substance
1, 1'-[1,4-Phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
Medicine name
Disease / condition
Treatment to mobilize progenitor cells prior to stem cell transplantation
Date of first decision
EU designation number

Sponsor's contact details

Genzyme Europe BV
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
Tel. +31 20 245 4000

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

Related content

How useful was this page?

Add your rating
1 rating